Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression

Area of Science:

• Biochemistry
• Hematology
• Lipid signaling

Background:

• Sphingosine-1-phosphate (S1P) is a lipid mediator regulating cellular functions.
• Its role in sickle cell disease (SCD), a hemolytic disorder, remains unclear.
• Erythrocytes store significant amounts of S1P.

Purpose of the Study:

• To investigate the involvement of S1P alterations in SCD pathophysiology.
• To identify the mechanisms underlying S1P elevation in SCD.
• To explore S1P-related therapeutic strategies for SCD.

Main Methods:

• Metabolomic screening of blood from mouse and human SCD models.
• Measurement of sphingosine kinase 1 (SPHK1) activity in erythrocytes.
• Assessment of S1P levels in plasma and erythrocytes.
• Evaluation of S1P's direct impact on erythrocyte sickling.

Main Results:

• S1P levels are significantly elevated in the blood of individuals with SCD.
• Elevated erythrocyte sphingosine kinase 1 (SPHK1) activity increases S1P levels in SCD.
• Increased S1P directly promotes erythrocyte sickling, independent of S1P receptors.
• SPHK1-mediated S1P elevation contributes to SCD progression in murine models.

Conclusions:

• SPHK1-mediated elevation of S1P in erythrocytes is a key factor in SCD pathogenesis.
• This mechanism directly contributes to erythrocyte sickling and disease progression.
• Targeting the SPHK1-S1P pathway presents a potential therapeutic avenue for SCD.